Dipeptidyl-peptidase-4 inhibitor, alogliptin, attenuates arterial inflammation and neointimal formation after injury in low-density lipoprotein (LDL) receptor-deficient mice

Journal of the American Heart Association
Koji AkitaHiroyuki Daida

Abstract

The results of recent studies suggest that dipeptidyl-peptidase-4 inhibitors have antiatherogenic effects. However, whether or not dipeptidyl-peptidase-4 inhibitors could suppress arterial inflammation and intimal hyperplasia after injury remains undetermined. The present study aims to clarify the anti-inflammatory effects of the dipeptidyl-peptidase-4 inhibitor, alogliptin (AGP), on the arteries of atherogenic low-density lipoprotein receptor-deficient (LKO) mice. We compared intimal hyperplasia in LKO mice 2 weeks after femoral artery injury using an external vascular cuff model. All mice received oral injection of AGP (20 mg/kg per day) or normal saline (control) once daily for 14 days. Fasting blood sugar levels, serum cholesterol levels, or blood pressure did not significantly differ between the 2 groups. Plasma levels of active glucagon-like peptide-1 were higher in the AGP than in the control LKO mice (22.2±1.9 versus 15.6±0.9 pg/mL; P<0.05). Compared with saline, AGP significantly reduced intimal hyperplasia (1087±127 versus 1896±140 μm(2); P<0.001) as well as the intima/media ratio (0.08±0.01 versus 0.16±0.02; P<0.001). Immunostaining showed that AGP reduced proliferating cells (proliferating cell nuclear antigen-posit...Continue Reading

References

Jun 1, 1990·Journal of the American College of Cardiology·J H IpJ H Chesebro
Jan 14, 1999·The New England Journal of Medicine·R Ross
Feb 13, 2001·The Journal of Clinical Investigation·T Collins, M I Cybulsky
Oct 3, 2002·The EMBO Journal·Joel L PomerantzDavid Baltimore
Nov 28, 2006·Biochimica Et Biophysica Acta·James A McCubreyRichard A Franklin
Feb 9, 2007·The Journal of Biological Chemistry·Kei OhnumaChikao Morimoto
Feb 16, 2008·Arteriosclerosis, Thrombosis, and Vascular Biology·Amanda C DoranColeen A McNamara
Jan 11, 2011·Biochemical and Biophysical Research Communications·Hiromasa GotoHirotaka Watada
Mar 15, 2011·Vascular Pharmacology·Zubair ShahSanjay Rajagopalan
May 12, 2011·Journal of Cardiovascular Pharmacology·Nga N TaYan Huang
Dec 8, 2011·Journal of Atherosclerosis and Thrombosis·Manabu KitagakiMakoto Kikuchi
Feb 11, 2012·Endocrine Reviews·John R Ussher, Daniel J Drucker
Jan 9, 2013·Nature Reviews. Cardiology·André J Scheen
Nov 29, 2013·The Annals of Pharmacotherapy·Courtney I JarvisDerek Charron
Mar 22, 2014·Expert Opinion on Pharmacotherapy·Yutaka Seino, Daisuke Yabe

❮ Previous
Next ❯

Citations

Apr 26, 2016·Mediators of Inflammation·Young-Sun Lee, Hee-Sook Jun
Apr 4, 2016·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Enzo Bonora, Massimo Cigolini
Sep 30, 2015·Cardiovascular Diabetology·Enrique Z Fisman, Alexander Tenenbaum
Nov 30, 2018·Expert Review of Clinical Pharmacology·Syed Raza ShahSteven Roark
Jun 18, 2017·Cardiovascular Diabetology·Lihua DuanJixin Zhong
Sep 13, 2017·BioMed Research International·Dirk von LewinskiHarald Sourij
Jul 30, 2020·Nature Communications·Laurie L BaggioDaniel J Drucker
May 29, 2018·Medicinal Research Reviews·Katarina TomovicAndrija Smelcerovic
Nov 23, 2016·Journal of Cardiovascular Pharmacology·Linnea ErikssonAnton Razuvaev
Feb 12, 2021·The Journal of Clinical Endocrinology and Metabolism·Kaitlin M Love, Zhenqi Liu
May 16, 2021·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Atsushi Tanaka, Koichi Node

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
PCR
nuclear translocation

Software Mentioned

Statistical Package for the Social Science ( SPSS )
NIH Image J

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.